Swedish Orphan Biovitrum AB has gained commercial rights from the Swiss based company PharmaSwiss SA, to distribute Relistor®, Deflux® and Solesta® in a territory including Western Europe, Czech Republic, Slovakia, Hungary and also for Relistor in Russia.
“I am delighted that we have expanded our successful partnership with PharmaSwiss and provide patients and physicians with additional treatment options that address unmet medical needs in each specific therapeutic category”, said Alan Raffensperger, senior vice president and Chief Operating Officer at Sobi.
Sobi will handle all commercial activities in the territory including launch, market and patient access and promotion activities, while PharmaSwiss will be responsible for manufacturing, providing the finished products and products’ information. The three new products that Sobi will distribute, one pharmaceutical and two medical devices, are all approved for specialty care indications.
In June 2013, Sobi announced its first distribution agreement with PharmaSwiss to market the products Megace®, Monopril®, Cefzil® and Duricef® approved for the treatment of indications within the oncology, cardio-vascular and anti-infective therapy areas.